Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer ... questions about Opdivo for squamous cell lung cancer treatment, talk with your doctor.

Surgery remains the mainstay of treatment for early-stage [non-small cell lung cancer (NSCLC)], regardless of age,” researchers wrote in the Journal of ...

25, 2025 — In recent years, cell ... treatment and mortality from data on over 500,000 lung cancer patients. This study suggests that immunotherapy may not be the optimal ... New, Rare Type of ...

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural ...

Surgery remains the mainstay of treatment for early-stage [non-small cell lung cancer (NSCLC)], regardless of age,” researchers wrote in the Journal of ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum ...